Thrombolytic therapy for acute ischemic stroke. Experience of SITS (Safe Implementation of Thrombolysis in Stroke) register;Tratamiento trombolítico en el ictus isquémico agudo en España: Experiencia del registro SITS (Safe Implementation of Thrombolysis in Stroke)

Neurologia

Volumn 24, Issue 5, 2009, Pages 288-291

  Rodriguez Yanez M ^a   Alvarez Sabin J ^a   Davalos A ^a   Diez Tejedor E ^a   Castillo, José ^a,b  

^a Comité SITS MOST España ^*  (Spain)

^b University Hospital of Santiago de Compostela   (Spain)

Author keywords

Acute stroke; Outcome; Spain; Thrombolytic therapy

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE;

ACUTE DISEASE; AGED; ARTICLE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROGNOSIS; SPAIN;

FIBRINOLYTIC AGENTS; HUMANS; PROGNOSIS; REGISTRIES; SPAIN; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 70049117146     PISSN: 02134853     EISSN: 15781968     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Instituto Nacional de Estadística [Internet]. Defunciones según la causa de muerte, 2006. Disponible en: www.ine.es.
2. World Health Organization. Preventing chronic diseases: a vital investment, 2005. Disponible en: http://www.who.int/chp/chronic-disease-report/ full-report.pdf.
3. Truelsen T, Piechowski-Jozwiak B, Bonita R, Mathers C, Bogousslavsky J, Boysen G. Stroke incidente and prevalence in Europe: a review of available data. Eur J Neurol 2006;13:581-98
4. Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke W, et al. Thrombolysis with alteplase for acute ischaemic stroke in Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007;369:275-82.
5. Colhoun HM, Hemingway H, Poulter NR. Socio-economic status and blood pressure: an overview analysis. J Hum Hypertens 1998;12:91-110.
6. Cavelaars A, Kunst A, Mackenbach JP. Socio-economic differences in risk factors for morbidity and mortality in the European Community: an international comparison. J Health Psychol 1997;2:353-72.
7. Van Doorslaer E, Wagstaff A, van der Burg H, Christiansen T, De Graeve D, Duchesne I, et al. Equity in the delivery of health care in Europe and the US. J Health Econ 2000;19:553-83.
8. European Medicines Evaluation Agency committee for human medical products. Opinion in Relation to the Revised Conditions for the Safe and Effective use of Actylise Following an Article 29 Referral. London: EMEA, 2006.
9. Wahlgren NG, Dávalos A, Fieschi C, Ground M, Hacke W, Kaste M, et al. The International Stroke Thrombolysis Register for safe implementation of thrombolysis in stroke (SITS). Cerebrovasc Dis 2001;11(Suppl. 4):79.
10. Bamford JM, Sandercock PAG, Warlow CP, Slattery J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1989;20:828.
11. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017-25.
12. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998;652:1245-51.
13. ATLANTIS, ECASS and NINDS Study Group Investigators. Early stroke treatment associated with better outcome: a pooled analysis of ATLANTIS, ECASS and NINDS rt-PA stroke trials. Presented at ASA meeting, San Antonio, February 2002.
14. Clark WM, Albers GW, Madden KP, Hamilton S. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators. Stroke 2000;31:811-6.
15. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue Plasminogen Activator for Acute Ischemic Stroke. N Eng J Med 1995;333:1581-7.
16. Paciaroni M, Agnelli G, Corea F, Ageno W, Alberti A, Lanari A, et al. Early hemorrhagic transformation of brain infarction: rate, predictive factors, and influence on clinical outcome: results of a prospective multicenter study. Stroke 2008;39:2249-56.
17. Tandberg Askevold E, Naess H, Thomassen L. Predictors for recanalization after intravenous thrombolysis in acute ischemic stroke. J Stroke Cerebrovasc Dis 2007;16:21-4.
18. Tsivgoulis G, Saqqur M, Sharma VK, Lao AY, Hoover SL, Alexandrov AV; CLOTBUST Investigators. Association of pretreatment ASPECTS scores with tPA-induced arterial recanalization in acute middle cerebral artery occlusion. J Neuroimaging 2008;18:56-61.
19. Kent DM, Selker HP, Ruthazer R, Bluhmki E, Hacke W. The stroke-thrombolytic predictive instrument: a predictive instrument for intravenous thrombolysis in acute ischemic stroke. Stroke 2006;37:2957-62.